Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine.
Gorak-Stolinska, P
; Weir, RE; Floyd, S; Lalor, MK; Stenson, S; Branson, K; Blitz, R; Luke, S; Nazareth, B; Ben-Smith, A; +2 more...Fine, PE; Dockrell, HM and
(2006)
Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine.
Vaccine, 24 (29-30).
pp. 5726-5733.
ISSN 0264-410X
DOI: 10.1016/j.vaccine.2006.04.037
; Weir, RE; Floyd, S; Lalor, MK; Stenson, S; Branson, K; Blitz, R; Luke, S; Nazareth, B; Ben-Smith, A; +2 more...Fine, PE; Dockrell, HM and
(2006)
Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine.
Vaccine, 24 (29-30).
pp. 5726-5733.
ISSN 0264-410X
DOI: 10.1016/j.vaccine.2006.04.037
The immunogenicity and reactogenicity, in British schoolchildren, of the newly introduced Danish-SSI 1331 BCG vaccine was compared with that of the previously used Glaxo-Evans 1077 BCG vaccine. Interferon-gamma (IFN-gamma) response to M. tuberculosis purified protein derivative (M.tb PPD) in a 6-day whole blood assay and delayed type hypersensitivity (DTH) to tuberculin PPD were determined before and 1 year after receiving BCG or no vaccination. Scar size was measured 1 year after vaccination. There was no evidence of a difference in immunogenicity (IFN-gamma and DTH conversion rates) but evidence of lower reactogenicity (scar size) with Danish-SSI 1331 compared to Glaxo-Evans 1077 vaccines.
Full text not available from this repository.
Downloads